Could a different dosing schedule improve breast cancer treatment?
NCT ID NCT06926920
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a different dose and schedule of the drug sacituzumab govitecan (Trodelvy) in people with advanced triple-negative breast cancer that has not responded to prior treatment. The trial has two phases: phase 1 checks safety and the best dose, and phase 2 measures how well the drug shrinks tumors and delays cancer growth. About 100 adults with this type of breast cancer will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sacituzumab govitecan (Trodelvy)
What this could lead to
If successful, this could offer a more effective or better-tolerated dosing option for people with advanced triple-negative breast cancer.
What could go wrong
This is an early-phase trial (phase 1/2) with only 100 participants, so results may not apply broadly. The drug can cause side effects like nausea, fatigue, and low blood cell counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
-
John Flynn Private Hospital
RECRUITINGTugun, Queensland, 4224, Australia
-
Los Angeles Cancer Network (LACN) - Good Sam
RECRUITINGLos Angeles, California, 90017, United States
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
-
Severance Hospital, Yonsei University Health System
NOT_YET_RECRUITINGSeoul, 03722, South Korea
-
Siteman Cancer Center
RECRUITINGSt Louis, Missouri, 63110, United States
-
St. Vincent's Hospital - Kinghorn Cancer Center
RECRUITINGDarlinghurst, New South Wales, 2010, Australia
-
Sunshine Coast University Private Hospital
RECRUITINGBirtinya, Queensland, 4575, Australia
-
Tennessee Oncology, PLLC
RECRUITINGNashville, Tennessee, 37203, United States
-
Texas Oncology - DFW
RECRUITINGDallas, Texas, 75246, United States
-
The University of Kansas Hospital
RECRUITINGWestwood, Kansas, 66205, United States
-
Virginia Oncology Associates
RECRUITINGNorfolk, Virginia, 23502, United States
-
West Cancer Centre
RECRUITINGGermantown, Tennessee, 38138, United States
-
Winship Cancer Institute - Emory University
RECRUITINGAtlanta, Georgia, 30322, United States